Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 3/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201538 | 0.93 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BALDH1A1 | |
| SCHEMBL318045 | 0.93 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BALDH1A1 | |
| SCHEMBL1200970 | 0.93 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BALDH1A1 | |
| SCHEMBL1200763 | 0.93 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BALDH1A1 | |
| SCHEMBL1200906 | 0.93 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BALDH1A1 | |
| SCHEMBL1108059 | 0.93 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BALDH1A1 | |
| SCHEMBL1108057 | 0.93 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BALDH1A1 | |
| SCHEMBL1201453 | 0.93 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BALDH1A1 | |
| SCHEMBL14085628 | 0.93 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BALDH1A1 | |
| SCHEMBL28765484 | 0.93 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682931-B2 | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | UBE INDUSTRIES, LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9623046-B2 | Amphiphilic Janus-dendrimers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-04-18 | — | — | US | disclosed |
| US-9527878-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-27 | — | — | US | disclosed |
| US-9517993-B2 | Antagonists of the toll-like receptor 1/2 complex | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-12-13 | — | — | US | disclosed |
| EP-3064489-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | Ube Industries, Ltd. (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | UBE INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-9370529-B2 | Tannin inhibitors of HIV | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160038520-A1 | TANNIN INHIBITORS OF HIV | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-02-11 | — | — | US | disclosed |
| US-20160024244-A1 | Periodic Nanostructures From Self Assembled Wedge-Type Block-Copolymers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-01-14 | — | — | US | disclosed |
| US-7772381-B2 | Efficient method to synthesize benzyl group-protected alpha-pentagalloylglucose (α-PGG) and its analogues | OHIO UNIVERSITY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2010-06-03 | — | — | US | disclosed |
| US-7700646-B2 | Compounds for use in the treatment of infection | THE UNIVERSITY OF LONDON, SCHOOL OF PHARMACY (GB) | 2010-04-20 | — | — | US | disclosed |
| WO-2009158487-A2 | TREATMENT OF NEPHROLITHIASIS AND UROLITHIASIS USING 1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOSE (PGG) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090111975-A1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | BIOSYNTH AS (NO) | 2009-04-30 | — | — | US | disclosed |
| US-20090011055-A1 | Plasminogen Activator Inhibitor-1 Inhibitors And Methods Of Use Thereof To Modulate Lipid Metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008131047-A2 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070021384-A1 | Compounds for use in the treatment of infection | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2007-01-25 | — | — | US | disclosed |
| WO-2004009094-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES MELLITIS | OHIO UNIVERSITY (US) | 2004-01-29 | — | — | WO | disclosed |
| US-5073448-A | Containing light stabilizers | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | SERPINE1, PLAT, SERPINB1 | PLA2G2A 321/4885TP53 4494/4885TSHR 1788/4885 |
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | SERPINE1, PLAT, SERPINB1 | PLA2G2A 321/4885TP53 4494/4885TSHR 1788/4885 |
| US-20090011055-A1 | Plasminogen Activator Inhibitor-1 Inhibitors And Methods Of Use Thereof To Modulate Lipid Metabolism | SERPINE1, PLAT, SERPINB1 | PLA2G2A 321/4885TP53 4494/4885TSHR 1788/4885 |
| US-20090111975-A1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | POR, SPR, G6PD | PLA2G2A 4366/4885TP53 3355/4885TSHR 4373/4885 |
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | SLCO1B1, SLCO2B1, SLCO1B3 | PLA2G2A 4116/4885TP53 2588/4885TSHR 1707/4885 |
| US-20070021384-A1 | Compounds for use in the treatment of infection | C9, APEH, GRHPR | PLA2G2A 3765/4885TP53 4455/4885TSHR 1571/4885 |
| US-20160038520-A1 | TANNIN INHIBITORS OF HIV | SERPINB1, TSN, FURIN | PLA2G2A 4631/4885TP53 2558/4885TSHR 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.